AlphaQuest LLC Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

AlphaQuest LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 86.9% in the third quarter, HoldingsChannel reports. The firm owned 662 shares of the medical research company’s stock after selling 4,388 shares during the quarter. AlphaQuest LLC’s holdings in IQVIA were worth $126,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Alliancebernstein L.P. lifted its position in IQVIA by 0.6% during the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after purchasing an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of IQVIA during the 2nd quarter valued at about $515,772,000. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after acquiring an additional 581,157 shares during the last quarter. Nordea Investment Management AB grew its position in IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after acquiring an additional 253,759 shares in the last quarter. Finally, Cantillon Capital Management LLC increased its stake in IQVIA by 27.3% during the third quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after acquiring an additional 413,256 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. Mizuho set a $266.00 price objective on IQVIA in a research note on Friday, January 9th. Jefferies Financial Group decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. TD Cowen lifted their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research report on Friday, February 6th. Finally, Evercore restated an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $238.20.

IQVIA Stock Performance

IQVIA stock opened at $168.78 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. The company has a market capitalization of $28.74 billion, a PE ratio of 21.47, a P/E/G ratio of 1.71 and a beta of 1.37. The company has a 50 day moving average price of $224.30 and a 200-day moving average price of $209.18. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.